ASCO 2014 Highlights

AZD9291, a Novel Mutation-Selective EGFR Inhibitor, May Overcome EGFR-TKI Resistance

Phoebe Starr

June 2014, Vol 5, No 5 - ASCO 2014 Highlights

Chicago, IL—AZD9291, a novel mutation-selective tyrosine kinase inhibitor (TKI), may become a treatment option for patients with advanced, EGFR-mutated non–small-cell lung cancer (NSCLC) that has progressed with standard EGFR inhibitors, according to results of a phase 1 study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing. [ Read More ]

Obesity Ups Death Risk in Premenopausal Patients with ER-Positive, but Not ER-Negative, Breast Cancer

Phoebe Starr

June 2014, Vol 5, No 5 - ASCO 2014 Highlights

Chicago, IL—Obesity increased the risk for breast cancer–associated death in premenopausal patients with estrogen receptor (ER)-positive breast cancer, had little effect in postmenopausal women with ER-positive disease, and had no effect in patients with ER-negative disease, according to results of a large study of 80,000 women with early breast cancer that were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting. [ Read More ]

Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses

Wayne Kuznar

June 2014, Vol 5, No 5 - ASCO 2014 Highlights

Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing. [ Read More ]